PROTEOME SCIENCES APPOINTS CHIEF SCIENTIFIC OFFICER

18 July 2006

Proteome Sciences plc ("Proteome Sciences" or "the Company") is pleased to announce that Dr. Peter Schulz-Knappe will join the Company on 1st August, 2006 as Research and Development Director/CSO. Dr. Schulz-Knappe will be splitting his responsibilities between the Company's Head Office in Cobham and its laboratories in Frankfurt and London.

Prior to its takeover by Digilab LLC in February 2006, Dr. Schulz-Knappe was CSO and founder of BioVision GmbH ("BioVision"), a company that has used mass spectrometry to quantify and sequence biomarkers in pharmacogenomics and personalised medicine through differential peptide display (peptidomics).

Formerly Head of the Department at the Lower Saxony Institute of Peptide Chemistry, Dr. Schulz-Knappe worked in cell biology and peptide and protein related science for 20 years and established a large network within the pharma, diagnostics and biotech industries. These have included strategic research alliances with many majors including Abbott, Novartis, Novo Nordisk, Astra Zeneca and Roche.

Commenting on the appointment of Dr. Schulz-Knappe, Christopher Pearce, Chief Executive of Proteome Sciences said:

"We are delighted that Dr. Schulz-Knappe will be joining us at this exciting stage of our development. Having recently entered into licences for our stroke biomarkers with two of the top ten global clinical diagnostic companies in high throughput screening, we are keen to expand the coverage to the other main players and to conclude similar agreements from our burgeoning portfolio of biomarkers in neurodegenerative disorders, cancer and kidney transplant rejection.

The recent signals from the US FDA of its intention to widen the scope of biomarker data for new drug applications is a significant and positive shift which should accelerate the pace of completion of other external licences and further increase confidence in our future prospects."